IAM
UTHR icon

Iridian Asset Management’s United Therapeutics UTHR Stock Holding History

Iridian Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,970,939
Closed -$259M – 89
2015
Q3 		$259M Buy
1,970,939
+418,190
+27% +$67.1M 2.19% 20
2015
Q2 		$270M Buy
1,552,749
+104,625
+7% +$18.8M 2.13% 19
2015
Q1 		$250M Buy
1,448,124
+439,404
+44% +$67M 2.1% 23
2014
Q4 		$131M Buy
1,008,720
+235,640
+30% +$30.4M 1.21% 36
2014
Q3 		$99.5M Buy
+773,080
New +$79.7M 1.03% 38

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Iridian Asset Management's UTHR Position: Q4 2015 in Review

Iridian Asset Management sold out of United Therapeutics (UTHR) in Q4 2015, closing a stake of 1,970,939 shares — an estimated $259M sold.

Iridian Asset Management first reported a position in UTHR in Q3 2014 and held it in 5 quarters. The position peaked at $270M in Q2 2015. 386 funds tracked by Wall St. Rank hold UTHR as of Q4 2015.

  • Iridian Asset Management reported no remaining United Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Iridian Asset Management sold 1,970,939 United Therapeutics shares in Q4 2015, an estimated $259M.
  • Iridian Asset Management first reported a position in United Therapeutics in Q3 2014 and held it in 5 quarters.
  • Iridian Asset Management's United Therapeutics position peaked at $270M in Q2 2015.
  • 386 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2015.

Based on Iridian Asset Management's 13F filing for Q4 2015, filed 5 Feb 2016.